Results 11 to 20 of about 327,495 (248)
Intermittent claudication [PDF]
Current Treatment Options in Cardiovascular Medicine, 2001 Intermittent claudication is the most common symptom in patients with peripheral arterial disease (PAD). As such, it is mandatory for clinicians to treat both the PAD-specific symptoms (to decrease functional impairment and thereby improve quality- of-life, as well as to decrease rates of amputation) and the underlying systemic atherosclerosis (and ...
Alan T., Hirsch, Laura, M Reich
openaire +2 more sources
Scandinavian Journal of Rehabilitation Medicine, 2020 Isokinetic plantar flexor peak torques (PT) and contractional work (CW) of the triceps surae muscle have been measured in 24 patients with peripheral arterial insufficiency and intermittent claudication and in 15 controls.
Björn Gerdle +3 more
semanticscholar +1 more source
BMJ Open Sport & Exercise Medicine, 2020 Peripheral artery disease (PAD) is caused by atherosclerotic narrowing of the arteries supplying the lower limbs often resulting in intermittent claudication, evident as pain or cramping while walking.
A. Harwood +7 more
semanticscholar +1 more source
Journal of Vascular Surgery, 2020 Background: The long-term benefit of revascularization for intermittent claudication is poorly understood. The aim of this study was to investigate the long-term effectiveness and cost-effectiveness compared with a noninvasive approach.
H. Djerf +5 more
semanticscholar +1 more source
Scandinavian Journal of Rehabilitation Medicine, 2020 The possibility of predicting the effect of training on the walking tolerance in intermittent claudication has been studied. After three months of supervised training in 54 patients, the maximal walking distance (MWD) increased by 67% and the painfree ...
T. Jonason, I. Ringqvist
semanticscholar +1 more source
Intermittent Claudication and Asymptomatic Peripheral Arterial Disease.
Deutsches Ärzteblatt International, 2020 BACKGROUND The conservative treatment of peripheral arterial disease (PAD), as recommended in current guidelines, encompasses measures such as lifestyle modification and risk-factor management.
G. Rümenapf +3 more
semanticscholar +1 more source
Naftidrofuryl for intermittent claudication [PDF]
Cochrane Database of Systematic Reviews, 2008 Lifestyle changes and cardiovascular prevention measures are a primary treatment for intermittent claudication (IC). Symptomatic treatment with vasoactive agents (Anatomic Therapeutic Chemical Classification (ATC) for medicines from the World Health Organisation class CO4A) is controversial.To evaluate evidence on the efficacy and safety of oral ...
Luc M. Van Bortel +4 more
openaire +4 more sources
Stages of health behavior change and factors associated with physical activity in patients with intermittent claudication [PDF]
, 2012 OBJECTIVE: To analyze, in people with intermittent claudication, the frequency of individuals who are in each of stages of health behavior change to practice physical activity, and analyze the association of these stages with the walking capacity ...
Barbosa, João Paulo dos Anjos Souza +7 more
core +2 more sources
Effect of supervised exercise on physical function and balance in patients with intermittent claudication [PDF]
, 2014 Background The aim of the study was to identify whether a standard supervised exercise programme (SEP) for patients with intermittent claudication improved specific measures of functional performance including balance. Methods A prospective observational
Chetter, I. C. +6 more
core +1 more source
Silence of the limbs: pharmacological symptomatic treatment of intermittent claudication [PDF]
, 2010 Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules.
De Backer, Gui +4 more
core +1 more source